Edwards Lifesciences Corporation (EW): Price and Financial Metrics


Edwards Lifesciences Corporation (EW)

Today's Latest Price: $85.52 USD

1.71 (-1.96%)

Updated Jan 22 7:00pm

Add EW to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 186 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

EW Stock Summary

  • Edwards Lifesciences Corp's market capitalization of $54,365,946,854 is ahead of 95.63% of US-listed equities.
  • EW's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2,190.3 -- higher than 98.02% of US-listed equities with positive expected earnings growth.
  • In terms of volatility of its share price, EW is more volatile than 93.42% of stocks we're observing.
  • Stocks that are quantitatively similar to EW, based on their financial statements, market capitalization, and price volatility, are BSX, PHG, ILMN, KLAC, and ADI.
  • EW's SEC filings can be seen here. And to visit Edwards Lifesciences Corp's official web site, go to www.edwards.com.

EW Stock Price Chart Interactive Chart >

Price chart for EW

EW Price/Volume Stats

Current price $85.52 52-week high $92.08
Prev. close $87.23 52-week low $51.51
Day low $85.21 Volume 3,278,900
Day high $87.37 Avg. volume 2,535,793
50-day MA $86.18 Dividend yield N/A
200-day MA $78.51 Market Cap 53.30B

Edwards Lifesciences Corporation (EW) Company Bio


Edwards Lifesciences provides products and technologies to treat structural heart disease and critically ill patients worldwide. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The company was founded in 1999 and is based in Irvine, California.

EW Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$85.52$6.23 -93%

Below please find a table outlining a discounted cash flow forecast for EW, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Edwards Lifesciences Corp ranked in the 10th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for EW, they are:

  • The company's compound free cash flow growth rate over the past 5.5 years comes in at -0.04%; that's greater than only 19.35% of US stocks we're applying DCF forecasting to.
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately merely 7.13% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than just 0% of stocks in its sector (Healthcare).


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-93%
1%-93%
2%-93%
3%-93%
4%-93%
5%-93%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as EW, try BHC, SRDX, COO, SIGA, and OSMT.


EW Latest News Stream


Event/Time News Detail
Loading, please wait...

EW Latest Social Stream


Loading social stream, please wait...

View Full EW Social Stream

Latest EW News From Around the Web

Below are the latest news stories about Edwards Lifesciences Corp that investors may wish to consider to help them evaluate EW as an investment opportunity.

What's in Store for Edwards Lifesciences in (EW) Q4 Earnings?

Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

Yahoo | January 20, 2021

E.W. Scripps Pops 13% After-Market On Billionaire Buffett’s 24.9% Stake

Shares of E.W. Scripps spiked 13% in Friday’s extended market trading after the TV station owner disclosed that Warren Buffett’s Berkshire Hathaway has a 24.9% passive stake in the company. According to an SEC filing, billionaire investor Buffett owns 23.1 million shares of E.W. Scripps (SSP), which are held in the form of a warrant exercisable within 60 days. Back in September, Buffett agreed to make a $600 million equity investment in E.W. Scripps to help the company buy broadcast network ION Media for $2.65 billion. In exchange, Berkshire received a warrant to purchase 23.1 million in Class A E.W. Scripps shares at $13 a piece. E.W.

Sharon Wrobel on TipRanks | January 18, 2021

Prosthetic Heart Valves Market Emerging Technology, Growth And Key Players Insights and Growing Demand | Edwards Lifesciences Corporation, Medtronic plc., Boston Scientific Corporation

The Prosthetic Heart Valves market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. Coherent Market Inisghts Research’s latest publication, titled Prosthetic

OpenPR | January 13, 2021

Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021 - Stocks News Feed

IRVINE, Calif., Jan. 13, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2020 after the market closes on Wednesday, January 27, 2021, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877)… Read More »Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021

Stocks News Feed | January 13, 2021

Edwards Lifesciences: TAVR, Mitral And Tricuspid Segments Are Each Meaningful Compounders

Investment Thesis We are bullish Edwards Lifesciences (NYSE:EW) shares and believe the name is worth visiting for those seeking exposure to valve therapies and cardiovascular interventions. EW hosts a robust portfolio that is well insulated, via diversified offerings within the valve surgery space, and this widens the company's economic bastion...

Zach Bristow on Seeking Alpha | January 11, 2021

Read More 'EW' Stories Here

EW Price Returns

1-mo -3.51%
3-mo 6.35%
6-mo 8.68%
1-year 11.33%
3-year 105.59%
5-year 219.90%
YTD -6.26%
2020 17.32%
2019 52.31%
2018 35.90%
2017 20.29%
2016 18.64%

Continue Researching EW

Here are a few links from around the web to help you further your research on Edwards Lifesciences Corp's stock as an investment opportunity:

Edwards Lifesciences Corp (EW) Stock Price | Nasdaq
Edwards Lifesciences Corp (EW) Stock Quote, History and News - Yahoo Finance
Edwards Lifesciences Corp (EW) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8606 seconds.